Roche John C 4
4 · HANOVER INSURANCE GROUP, INC. · Filed Apr 1, 2025
Insider Transaction Report
Form 4
Roche John C
DirectorPresident and CEO
Transactions
- Sale
Common Stock
2025-03-28$175.03/sh−400$70,012→ 124,277.851 total - Exercise/Conversion
Common Stock
2025-03-31$77.91/sh+301$23,451→ 124,714.708 total - Exercise/Conversion
Common Stock
2025-03-28$77.91/sh+400$31,164→ 124,677.851 total - Award
Common Stock
2025-03-28+135.857→ 124,413.708 total - Sale
Common Stock
2025-03-31$175.00/sh−301$52,675→ 124,413.708 total - Exercise/Conversion
Common Stock Option (right to buy)
2025-03-28−400→ 9,207 totalExercise: $77.91Exp: 2026-02-23→ Common Stock (400 underlying) - Exercise/Conversion
Common Stock Option (right to buy)
2025-03-31−301→ 8,906 totalExercise: $77.91Exp: 2026-02-23→ Common Stock (301 underlying)
Footnotes (4)
- [F1]Exercise of options scheduled to expire in February 2026 and resulting sale of shares reported were effected pursuant to a pre-established Rule 10b5-1 Trading Plan adopted on November 5, 2024.
- [F2]Does not include 14,454 shares held by the Reporting Person's spouse.
- [F3]Grant of restricted stock units ("RSUs") under the Issuer's 2022 Long-Term Incentive Plan ("2022 LTIP") in connection with the accrual of dividend equivalent rights associated with RSUs previously granted under the Issuer's 2022 LTIP. Such RSUs vest on the third anniversary of the date of grant of the original underlying RSUs.
- [F4]The option, representing the right to purchase a total of 21,413 shares, vested 1/3 on each of 2/23/17, 2/23/18 and 2/23/19.